Pharmacology 2: Renal Dosing Flashcards

1
Q

What is the importance of dosing medications based on renal function?

A
  1. Avoid accumulation of drug and/or active metabolites
  2. Optimize pharmacologic effort
  3. Provide cost-effective therapy (reduced dose with equivalent efficacy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are some examples of non-renal elimination?

A

Liver, feces, sweat

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are 3 factors in renal elimination?

A
  1. Glomerular filtration
  2. Tubular secretion
  3. Tubular reabsorption
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What does the GFR represent?

A

The functional status of the kindeys (as renal mass decreases secondary to aging or disease) there is a progressive decrease in GFR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is a normal GFR?

A

120 ml/min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

For medications that require adjustments in kidney disease, what is the GFR when you would do this?

A

Below 50-60 (this is where the drug will begin to accumulate)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the GFR in stage 1 kidney disease?

A

Greater or equal to 90

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the GFR in stage 2 kidney disease?

A

60-89

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the GFR in stage 3 kidney disease?

A

30-59

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the GFR in stage 4 kidney disease?

A

15-29

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the GFR in stage 5 kidney disease?

A

Under 15 or dialysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the drug characteristics that are predictive of a need to modify dosing in patients with renal disease?

A
  1. Potential change in volume of distribution
  2. % renal clearance
  3. Poor removal by dialysis
  4. Potential for adverse response
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are 3 situations where there might be a potential change in the volume of distribution?

A
  1. Acidic drugs (increase BUN and excrete N leading to uremia which will displace acidic drugs from their binding sites)
  2. Highly protein bound drugs (over 90%)
  3. Small volume of distribution
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are 2 examples of acidic drugs?

A

Phenytoin and warfarin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

If a drug is bound to protein is it pharmacologically active?

A

NO..in renal patients, they usually have low protein stores and produce less albumin causing more active drug because not as much is bound to protein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the % cutoff of amount of a dose eliminate unchanged in urine where you worry about renal dosing?

A

30%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are 2 features of a drug what can result in poor removal by dialysis?

A
  1. Highly protein bound (because it can’t cross the dialysis membrane)
  2. Large volume of distribution
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What 2 drugs specifically do we worry about with potential for adverse response related to issues with renal clearance?

A
  1. Digoxin
  2. Aminoglycosides
    - Worry about active metabolites that depend on the kidney for elimination
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What 4 criteria make for the ideal marker?

A
  1. Unrestricted (100%) diffusion across the glomerulus
  2. No additional or little tubular secretion or loss by reabsorption
  3. No additional metabolism by renal tubular cells
  4. Doesn’t alter renal function
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Which marker is used mostly in clinical trials?

A

Inulin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Which 2 markers are used more in practice?

A

Serum creatinine and creatinine clearance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the most common clinical test for assessment of renal function to assess GFR?

A

Creatinine clearance (can be measured or estimated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is creatinine?

A

Product of creatine metabolism from muscle (directly dependent on muscle mass)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What is the normal range of serum creatinine?

A

0.5-1.5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

If creatinine clearance decreases, what does serum creatinine do?

A

Rise

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What % of serum creatinine is filtered and secreted?

A

90% filtered and 10% secreted (minimal reabsorption)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

If serum creatinine doubles, what % loss of GFR does this correlate to?

A

50%

28
Q

Is creatinine clearance better for long term or short term evaluation?

A

Long term (over time)

29
Q

What are 5 factors that can increase serum creatinine?

A
  1. Kidney disease (also muscle trauma)
  2. Ingestion of cooked meat
  3. Trimethoprim, cimetidine
  4. Flucytosine, some cephalosporins
  5. Ketoacidosis
30
Q

What can decrease serum creatinine?

A

Malnutrition

31
Q

Do you know the equation for creatinine clearance?

A

(Urine concentration * Urine flow rate)/Plasma concentration

32
Q

What are disadvantages to 24 hour urine collection to measure creatinine clearance?

A

It’s inconvenient, takes time to get results, and isn’t reliable due to compliance

33
Q

What is the most common formula used to estimate creatinine clearance?

A

Cockcroft-Gault

34
Q

What 2 formulas are used for creatinine clearance that are easier to use because they don’t require weight?

A

MDRD and CKD-EPI

35
Q

Which equation is the most frequent value provided by laboratories to estimate GFR and stage kidney disease?

A

MDRD

36
Q

Which equation was developed to more accurately assess GFR over 60ml/Min (compared to MDRD)?

A

CKD-EPI

37
Q

What are the 3 benefits of MDRD and CKD-EPI equations?

A
  1. Simplified (computer can do it)
  2. Validates in various subgroups
  3. Don’t require weight for calculation
38
Q

Limitations of MDRD and CKD-EPI equations?

A
  1. Not validated in children 18
  2. Limited data in elderly (over 70) –> Low serum creatinine concentrations may overestimate GFR
  3. Not routinely used in studies to determine medication dosing
39
Q

What are 3 fratures of the Cockgroft-Gault equation (used most frequently for adults)?

A
  1. It is useful for estimating GFR in stable renal function (chronic renal failure)
  2. It is not useful in estimating rapidly changing renal function (acute renal failure)
  3. Low serum concentrations may alter results (overestimates true GFR)
40
Q

4 Considerations in drug dosing in renally impaired patients?

A
  1. Degree of renal elimination
  2. Degree of renal insufficiency
  3. Therapeutic window
  4. Treatment indication/severity of illness
41
Q

What are 2 options for dosing adjustments?

A
  1. Change the dose

2. Change the dosing interval

42
Q

Did you look at the list he gave us of drugs requiring major dosing reduction?

A

GO DO IT

43
Q

Consequence of aminoglycoside accumulation?

A

Ototoxicity and nephrotoxicity

44
Q

Consequence of vancomycin accumulation?

A

Nephrotoxicity

45
Q

Consequence of imipenem accumulation?

A

Seizures

46
Q

Consequence of gabapentin accumulation?

A

Ataxia, dizziness, nystagumus, and somnolence

47
Q

Consequence of valacyclovir accumulation?

A

CNS and renal failure

48
Q

Consequence of famotidine accumulation?

A

Confusion

49
Q

Consequence of lithium accumulation?

A

Sedation, confusion, seizures

50
Q

Consequence of enoxaparin accumulation?

A

Bleeding

51
Q

What are drug dependent factors in medication dosing in dialysis?

A
  1. Molecular weight
  2. Protein binding
  3. Volume of distribution
  4. Water solubility
  5. Plasma clearance
52
Q

What are dialysis dependent factors in medication dosing in dialysis?

A
  1. Dialysis membrane

2. Blood and dialysate flow rate

53
Q

What size molecules pass easier through a dialysis membrane?

A

SMALL ONES

54
Q

Does Chronic ambulatory peritoneal dialysis or hemodialysis have larger pores?

A

CAPD

55
Q

Are medications that are bound to protein likely to pass through a hemodialysis filter?

A

NO

56
Q

Does a larger or smaller volume of distribution correlated to a lower likelihood of being removed through dialysis?

A

Larger (disperse widely to tissues)

57
Q

What types of drugs have a larger volume of distribution?

A

High degree of lipid solubility

58
Q

If nonrenal clearance is large compared to renal clearance, is dialysis likely to contribute to drug removal?

A

NOPE

59
Q

What is clearance equal too?

A

Renal and non-renal clearance

60
Q

What % must dialysis increase renal clearance by to be considered clinically significant?

A

30%

61
Q

If the blood flow rate is higher, what does this mean with amount of drug delivered?

A

More drug is delivered

62
Q

If the dialysate flow rate is high, is the likelihood to drug rmeoval higher or lower?

A

Lower

63
Q

If a drug is not removed by hemodialysis, is it likely to be removed by CAPD?

A

NO

64
Q

What is supplemental dosing of a drug based on?

A

What % of the drug was removed during dialysis (if more than 30% of clearance was by dialysis)

65
Q

What is continuous renal replacement therapy (CRRT)?

A

A technique that allows for continuous hemodialysis, hemofiltration, or hemdiafiltration using pump- assisted blood circulation that is continued for 24 hours (make sure to give supplemental doses to maintian adequate replacement of medications removed via dialysis)

66
Q

What are the 2 features relating to the economic impact of renal dosing?

A
  1. Direct cost savings (patient taking less drug)

2. Indirect cost savings (decreased risk of adverse affect